| __timestamp | Amphastar Pharmaceuticals, Inc. | BeiGene, Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 6930000 |
| Thursday, January 1, 2015 | 46974000 | 7311000 |
| Friday, January 1, 2016 | 47298000 | 20097000 |
| Sunday, January 1, 2017 | 50918000 | 62602000 |
| Monday, January 1, 2018 | 58044000 | 195385000 |
| Tuesday, January 1, 2019 | 63109000 | 388249000 |
| Wednesday, January 1, 2020 | 65157000 | 600176000 |
| Friday, January 1, 2021 | 68920000 | 990123000 |
| Saturday, January 1, 2022 | 66592000 | 1277852000 |
| Sunday, January 1, 2023 | 80393000 | 1504501000 |
Unveiling the hidden dimensions of data
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, BeiGene, Ltd. and Amphastar Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenditures. BeiGene's SG&A expenses skyrocketed by over 21,000%, from a modest $6.93 million in 2014 to a staggering $1.5 billion in 2023. This reflects their aggressive expansion and investment in research and development. In contrast, Amphastar's expenses grew by approximately 99%, from $40 million to $80 million, indicating a more conservative growth strategy. This divergence highlights the different paths these companies have taken in the biopharma landscape. As BeiGene continues to invest heavily in its future, Amphastar's steady approach may offer a more sustainable model in the long run.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and BeiGene, Ltd.
BeiGene, Ltd. and Exelixis, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Alkermes plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.